文献速递淋巴瘤

伊布替尼联合维奈克拉治疗复发或难治性套细胞淋巴瘤的剂量探索研究

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.
PubMed 文献 · Blood Adv · 2022-01-01

确定最优组合为维奈克拉200mg联合伊布替尼420mg,总缓解率93.8%(95%CI: 73.6%–99.7%),剂量限制性毒性发生率6.2%(95%CI: 0.3%–26.4%)。更高剂量组合未增加缓解获益且毒性更高。

要点

  • 最优剂量组合为维奈克拉200mg联合伊布替尼420mg,总缓解率93.8%。
  • 维奈克拉起始100mg时发生1例肿瘤溶解综合征,起始20mg时未见。
  • 更高剂量组合未提高缓解率且毒性增加,各剂量组均观察到耐药。

核心结论

  • 维奈克拉200mg联合伊布替尼420mg为基于疗效和毒性的最优剂量组合,总缓解率93.8%(95%CI: 73.6%–99.7%),剂量限制性毒性发生率6.2%(95%CI: 0.3%–26.4%)。

研究设计与样本

  • 评估6种组合:伊布替尼280mg、420mg、560mg口服每日联合维奈克拉最大剂量200mg或400mg口服每日。
  • 维奈克拉先于伊布替尼启动,起始100mg,发生肿瘤溶解综合征后改为起始20mg,按分配剂量水平递增;联合治疗持续6个28天周期。

主要发现

  • 最优组合维奈克拉200mg联合伊布替尼420mg的总缓解率93.8%(95%CI: 73.6%–99.7%),剂量限制性毒性发生率6.2%(95%CI: 0.3%–26.4%)。
  • 所有组总缓解率82.3%(28/34;95%CI: 65.5%–93.2%),完全缓解率42.4%(14/33;95%CI: 25.5%–60.8%)。
  • 维奈克拉起始100mg时发生1例肿瘤溶解综合征,起始20mg时未见肿瘤溶解综合征。
  • 更高剂量组合未观察到缓解获益且毒性更高;几乎所有组均观察到耐药。
  • 1例参与者未分配至伊布替尼560mg联合维奈克拉400mg组。

关键数值与推荐

  • 最优剂量组合:维奈克拉200mg口服每日联合伊布替尼420mg口服每日。
  • 维奈克拉起始剂量:100mg(发生肿瘤溶解综合征后改为20mg),先于伊布替尼启动并按剂量水平递增。
  • 联合治疗持续6个28天周期。

临床怎么用

  • 对于未接受过BTK抑制剂的复发或难治性套细胞淋巴瘤患者,可考虑维奈克拉200mg联合伊布替尼420mg。
  • 维奈克拉起始剂量建议采用20mg以降低肿瘤溶解综合征风险,尤其适用于非高危患者。
  • 不推荐使用更高剂量组合,因未增加缓解获益且毒性更高。

局限性

  • 研究为小样本队列,更高剂量组合与最优组合的比较受限于小队列的局限性。
  • 1例参与者未分配至伊布替尼560mg联合维奈克拉400mg组。
  • 几乎所有组均观察到耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapsed Mantle cell lymphoma (MCL) is often treated with Bruton's tyrosine kinase inhibitors (BTKi); however, post-BTKi relapse can be challenging. Adding venetoclax (VEN) to ibrutinib (IBR) has shown synergy in preclinical MCL models. Prior MCL studies of the combination show promising efficacy but have conducted limited dose finding. We sought to identify the optimal dosing combination, based on efficacy and toxicity, utilizing a continual reassessment method of 6 combinations of IBR (280 mg, 420 mg, and 560 mg by mouth daily) and VEN (max dose of 200 mg and 400 mg by mouth daily). Eligible participants were not previously exposed to BTKi and not high risk for tumor lysis syndrome (TLS). VEN, initiated first at 100 mg, then at 20 mg by mouth daily after a TLS event, was started prior to adding IBR and ramped-up based on the dose level assigned. Combination treatment continued for six 28-day cycles. Thirty-five participants were enrolled and treated. One TLS event occurred with starting dose of 100 mg VEN; no TLS was seen with 20 mg. The optimal dosing combination was considered to be VEN 200 mg and IBR 420 mg with an overall response rate (ORR) of 93.8% (95% CI: 73.6% to 99.7%) and DLT incidence of 6.2% (95% CI: 0.3% to 26.4%). ORR for all arms was 82.3% (28/34; 95% CI: 65.5% to 93.2%) with a complete response (CR) rate of 42.4% (14/33; 95% CI: 25.5% to 60.8%). A participant was not allocated to IBR 560 mg and VEN 400 mg. ORR benefit was not seen with higher dosing combinations and toxicity was higher; a comparison made within the limitations of small cohorts. Resistance was seen in nearly all arms. This trial was registered at www.clinicaltrials.gov #NCT02419560.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Portell CA, Wages NA, Kahl BS, et al. Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma. Blood Adv. 2022. PMID: 34700344. doi:10.1182/bloodadvances.2021005357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。